Cath Lab Gets Highest Safety Rating

The New York State Department of Health recently awarded The Mount Sinai Hospital’s Cardiac Catheterization (Cath) Laboratory the highest “two-star” safety rating for percutaneous coronary interventions (PCI) in overall and nonemergency cases. This marks the 16th consecutive year that the Cath Lab, or one of its physicians, has received this prestigious two-star rating for safety when performing PCI. The minimally invasive procedure, also known as angioplasty, is used to diagnose and treat patients with heart disease or blocked arteries.

(more…)

Mount Sinai Presents Groundbreaking Findings on Heart Procedure

In a groundbreaking, multi-centered randomized trial published in The New England Journal of Medicine, researchers, co-led by Mount Sinai’s David H. Adams, MD, determined that a catheter-based heart procedure to replace an aortic valve was superior to surgery for patients who have symptomatic severe aortic stenosis with increased risks. The findings, based on a clinical trial involving 795 patients treated at 45 institutions across the nation, were simultaneously presented by Dr. Adams at the 63rd Annual Scientific Session of the American College of Cardiology on Saturday, March 29, and represent a major advance for heart patients who are at high risk for surgery.

(more…)

A National Goal: Improving Cardiovascular Health and Quality of Life

Chronic diseases, such as heart disease, cancer and diabetes, are responsible for seven out of every 10 deaths among Americans each year, and many of the risk factors that contribute to the development of these diseases are preventable. Healthy People 2020, an initiative of the U.S. Department of Health and Human Services (HHS), aims to improve the health of all Americans by providing science-based, 10-year national objectives. (more…)

Can Exercise Replace Drugs?

Can exercise replace drugs? A study recently published in BMJ (formerly the British Medical Journal) asked this question for four chronic conditions: coronary artery disease, pre-diabetes, stroke and heart failure. The study, which included more than 330,000 patients, was a “meta-analyses.” In other words, it compiled data from previously published controlled trials that looked at the effects of exercise or drug therapy on survival for the illnesses in question. (more…)

Blazing a New Trail in the Treatment of Heart Disease

An injectable nanoparticle that delivers HMG-CoA reductase inhibitors, or statins, which directly inhibit atherosclerotic plaque inflammation could represent a new frontier in the treatment of heart disease. This novel approach is being developed by researchers at Icahn School of Medicine at Mount Sinai, who have seen promising results in mice models and plan to translate their findings to humans within the next few years.

(more…)

Pin It on Pinterest